

40. O'Brien TR, George JR, Holmberg SD. Human immunodeficiency virus type 2 infection in the United States: epidemiology, diagnosis, and public health implications. *JAMA*. 1992; 267:2775-9.
41. DeCock KM, Porter A, Kouadio J, et al. Cross-reactivity on Western blots in HIV-1 and HIV-2 infections. *AIDS*. 1991;5:859-60.
42. Myers RA, Patel JD, Joseph JM. Identifying HIV-2 seropositive individuals by reevaluating HIV-1 indeterminate sera. *J Acquir Immune Defic Syndr*. 1992;5:417-23.
43. George JR, Rayfield MA, Phillips S, et al. Efficacies of U.S. Food and Drug Administration-licensed HIV-1 screening enzyme immunoassays for detecting antibodies to HIV-2. *AIDS*. 1990; 4:321-6.
44. Schumacher RT, Howard J, Ayres L. Cross-reactivity of anti-HIV-2 positive serum in U.S. FDA licensed screening tests for anti-HIV-1 [Abstract C 745]. San Francisco, CA: Presented at the Sixth International Conference on AIDS, June 20-23, 1990.
45. Drabick JJ, Horning VL, Lennox JL, et al. A retrospective analysis of diseases associated with indeterminate HIV Western blot patterns. *Milit Med*. 1991;156:93-6.
46. Celum CL, Coombs RW, Murphy VM, et al. Etiologies of indeterminate HIV-1 Western blots: autoantibodies, alloimmunization, and HIV-1 seroconversion [Abstract 4889]. Amsterdam, The Netherlands: VIII International Conference on AIDS, July 1992.
47. Handsfield HH, Wandell M, Goldstein L, Shriver K, Cooperative Study Group. Screening and diagnostic performance of EIA for antibodies to LAV. *J Clin Microbiol*. 1987;25:879-84.
48. Sayers MH, Beatty PG, Hansen JA. HLA antibodies as a cause of false-positive reactions in screening enzyme immunoassays for antibodies to human T-lymphotropic virus type III. *Transfusion*. 1986;26:113-5.
49. Working group on HIV testing of pregnant women and newborns. *JAMA*. 1990;264:2416-20.
50. Nelikin D, Tancredi L. *Dangerous diagnostics: the social power of biological information*. New York: Basic Books, 1989.
51. Haynes RB, Sackett DL, Taylor DW, Gibson ES, Johnson AL. Increased absenteeism from work after detection and labeling of hypertensive patients. *N Engl J Med*. 1978;244:741-4.
52. Johnston ME, Gibson ES, Terry CW, et al. Effects of labelling on income, work, and social function among hypertensive employees. *J Chron Dis*. 1984;37:417-23.
53. Burton BK, Dillard RG, Clark EN. The psychological impact for false-positive elevations of maternal serum alpha-fetoprotein. *Am J Obstet Gynecol*. 1985;151:77-82.
54. Public health uses of HIV-infection reports—South Carolina, 1986-1991. *MMWR*. 1992;41:245-9.
55. Roberts CR. Laboratory diagnosis of retroviral infections. *Dermatol Clin*. 1991;9:1-12.
56. Murphy VM, Celum CL, Roberts CR, et al. Recombinant antigen and synthetic peptide assays as supplemental tests for indeterminate HIV-1 Western blots [Abstract 4888]. Amsterdam, The Netherlands: VIII International Conference on AIDS, July 1992.
57. Recommended testing protocol to clarify status of donors with a reactive anti-HIV screening test. Washington, DC: Office of Biologics Research and Review, Center for Drugs and Biologics, U.S. Food and Drug Administration, 1987.

Correction

The order of authors' names was incorrect in the article, "Call Nights and Patient Care: Effects on Inpatients at One Teaching Hospital," which appeared in the July/August issue (*J Gen Intern Med*. 1992;7:405-10). The correct order is: Steven D. Hillson, MD, Eugene C. Rich, MD, Bryan Dowd, PhD, Michael G. Luxenberg, PhD.